Macrophage Activation Syndrome as a Severe Manifestation of Adult’s Still’s Disease. Hemophagocytic Cells in Ascites

Síndrome de activación macrofágica como complicación severa de la enfermedad de Still del adulto. Células hemofagocíticas en líquido ascítico

To the Editor:

Macrophage activation syndrome (MAS) occurs in a minority of patients with adult Still’s disease (ASD).\(^1,2\) It can be the diseases’ first manifestation or be triggered by an infection or change in treatment.\(^3\) Two cases are presented.

The first case is a 30-year-old woman with ASD, who came to the ER with a fever lasting for one week that did not improve with antibiotics, so she was admitted to the Rheumatology department. During admission, treatment with ceftriaxone and glucocorticoids (GC) mg/kg was started, and multiple complementary tests performed: blood culture positive for *pneumococcus* and positive serology for *cytomegalovirus*; analytically: hepatitis, elevated acute phase reactants (APR), hyperferritinemia, hypertriglyceridemia, thrombocytopenia, and anemia, in addition to splenomegaly in the computed tomography (CT).

Despite treatment, evolution was unfavorable, with persistent thrombocytopenia and declining ESR. With these data, we decided to perform a bone marrow biopsy (BMB), observing hemophagocytic cells (HC), diagnosing MAS and initiating treatment with cyclosporine (CSP) 5 mg/kg/day and 60 GC mg/day, with progressive improvement.

The second case is a 35-year-old woman who presented with fever, a sore throat, musculoskeletal pain, vomiting and rash for a week, diagnosed as the flu. Three days later she came to the ER because of persistent fever and rash, and the onset of lymphadenopathy, and was hospitalized. During admission, treatment was started with ceftriaxone and gentamicin; associated infection and autoimmunity was ruled out. Analytically she presented: anemia, elevated APR, hepatitis, hyperferritinemia, hypertriglyceridemia, impaired renal function and ascites. A CT was performed, which reported a systemic infection with lymphadenopathy and hepatosplenomegaly.

The initial suspicion was ASD, starting GC therapy at a dose of 1 mg/kg/day and presenting an initial improvement. Subsequently, the fever persisted and skin lesions progressed, added to respiratory and renal failure, which led to her transfer to the Intensive Care Unit (ICU) of our hospital. On admission to the ICU, we performed a BMB, ascites analysis, observing HC in both (Fig. 1). She was diagnosed as MAS. Evolution was poor despite GC, so we added CSP 5 mg/kg/day, with partial improvement and anakinra 100 mg/day. The evolution was favorable, so she was transferred to the rheumatology department, where after a few days she was discharged.

Both conditions share several features, such as fever, hepatosplenomegaly, lymphadenopathy, hepatitis, coagulopathy and hyperferritinemia, and often are indistinguishable.\(^2,3\) Pleuritis, acute respiratory distress syndrome and pancytopenia are more common in the MAS\(^1,2\) and cutaneous and articular affection in ASD.\(^2,3\) Leukopenia, thrombocytopenia and hypertriglyceridemia are not common in ASD, so these could serve as warning signs\(^1,2\); additionally, hyperferritinemia is generally higher in MAS.\(^2,4\)

Most of the cases described in the literature have been treated with GC, immunoglobulins, CSP and biological drugs.\(^1,2\) Both conditions share certain pathophysiologic characteristics such as the production factor tumor necrosis α and interleukins (IL), IL-1, IL-6, IL-8 and IL-18, with these being potential therapeutic targets.\(^5,6\)

The first patient probably presented MAS after a triggering infection. We hypothesize that the MAS in ASD can occur after a change in treatment or an infection; the most studied is the Epstein–Barr virus infection, but it has also been described\(^2,3,6\) in cases of *cytomegalovirus*.

Patient 2 presented HC in ascites; the first case was described in 2007 in a patient with liver cirrhosis and *Escherichia coli* infection.\(^7\) In addition, cases described with HC in\(^8,9\) pleural fluid and in cerebrospinal fluid.\(^10\)

---

Conflict of Interest

The authors have no disclosures to make.

References


César Egües Dubuc,* Miren Uriarte Ecenarro,
Nerea Errazquin Aguirre, Joaquín Belzunegui Otano

Servicio de Reumatología, Hospital Universitario Donostia,
San Sebastián, Guipúzcoa, Spain

*Corresponding author.
E-mail address: toneeguesdubuc@hotmail.com (C. Egües Dubuc).